ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Update

ProPhase Labs, Inc. (NASDAQ:PRPH) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 4,420,000 shares, a growth of 5,106.1% from the January 31st total of 84,900 shares. Based on an average daily volume of 8,590,000 shares, the short-interest ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on ProPhase Labs in a research report on Tuesday. They set a “sell” rating on the stock.

ProPhase Labs Stock Performance

Shares of PRPH stock opened at $0.45 on Friday. ProPhase Labs has a 1-year low of $0.22 and a 1-year high of $7.48. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $10.71 million, a price-to-earnings ratio of -0.36 and a beta of -0.37. The stock’s fifty day simple moving average is $0.52 and its 200-day simple moving average is $1.41.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PRPH. SVB Wealth LLC purchased a new position in shares of ProPhase Labs during the fourth quarter valued at $36,000. Squarepoint Ops LLC purchased a new position in shares of ProPhase Labs during the fourth quarter valued at $40,000. Warberg Asset Management LLC purchased a new position in shares of ProPhase Labs during the fourth quarter valued at $77,000. Perritt Capital Management Inc grew its holdings in shares of ProPhase Labs by 129.1% during the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock valued at $144,000 after buying an additional 107,068 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of ProPhase Labs by 26.6% during the fourth quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock valued at $154,000 after buying an additional 42,793 shares in the last quarter. Hedge funds and other institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.